Biotech News
Related news
AVIRAtea2026-05-27 11:00 EST
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
ASMBAssembly Biosciences2026-05-13 06:00 EST
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
IMNNImunon2026-03-31 12:00 EST
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
IMNNImunon2025-11-04 13:05 EST
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
MBRXMoleculin Biotech, Inc.2026-05-21 21:02 EST
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
ANTXAN2 Therapeutics2026-05-21 11:00 EST
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
OGENOragenics2026-05-19 12:45 EST
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
Atea
Antiviral Therapeutics Company Atea Pharmaceuticals develops oral antiviral combinations for serious viral diseases. Hepatitis C Regimen The lead regimen combines nucleotide polymerase inhibitor bemnifosbuvir with NS5A inhibitor ruzasvir as a short-duration, ribavirin-free treatment for hepatitis C. Global Phase 3 Program C-BEYOND covers...
Recent company news
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
AVIRAtea2026-06-25 11:00 EST
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
AVIRAtea2026-05-27 11:00 EST
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Stock data
- Close
- 4.99 USD
- Market cap
- 341.72M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States